Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) announced a delay in filing its Form 10-Q for Q1 2020 due to the COVID-19 pandemic, with plans to report financial results on June 18, 2020. The company reported preliminary revenue of $1.1 million and cash equivalents of $8.1 million as of March 31, 2020. Bionano is suspending its 2020 guidance amid uncertainties caused by the pandemic. Despite challenges, the company is experiencing increased interest in its Saphyr system, with new placements and ongoing operational capabilities. Recent highlights include fundraising and new collaborations in COVID-19 genomic studies.